Printer Friendly

MACRONEX APPOINTS NEW PRESIDENT AND CEO

 MACRONEX APPOINTS NEW PRESIDENT AND CEO
 RESEARCH TRIANGLE PARK, N.C., Oct. 16 /PRNewswire/ -- Macronex, Inc.


today announced it has appointed Dennis D. Burns as president and chief executive officer. Mr. Burns brings to the company 10 years of experience in biotechnology management.
 "We are very fortunate to have Dennis on our team. He will be invaluable to Macronex as it expands its staff and focuses its development and collaboration activities," said Paul Jones, one of the founders of Macronex. "His past accomplishments in the industry are evidence of his great leadership abilities."
 Mr. Burns replaces Jones, who was acting president while Macronex searched for its top executive. Mr. Jones now becomes executive vice president for corporate development.
 Mr. Burns, 47, was a senior executive at Johnson & Johnson for 10 years, where he played a major role in strengthening that company's presence in the biotechnology arena.
 Prior to joining Macronex, Mr. Burns was vice president of licensing and international development for Johnson & Johnson's OrthoBiotech, where he managed overseas market development and negotiated a number of strategic alliances and collaborations. Previously, as director of immunobiology operations at Ortho, Mr. Burns directed the development of the first monoclonal antibody approved for human therapy, Otrhoclone OKT3. In addition, while at Johnson & Johnson, Mr. Burns set up and managed a new business unit which developed biotech products for diagnostic imaging.
 Mr. Burns appointment comes at a time when Macronex is building its capital resources and sharpening its strategic goals. The company recently raised $4.5 million in a second round of private financing.
 Mr. Burns received a B.S. in Biology from Manhattan College and did post-graduate work at Yale University School of Medicine.
 Macronex, a biopharmaceutical discovery and development company, based near Research Triangle Park, was founded in 1990 to exploit scientific advances made in the laboratories of its Duke University Medical Center-based founders. The company is developing therapeutics for acute and chronic inflammatory and autoimmune diseases.
 -0- 10/16/92
 /CONTACT: Paul Jones, executive vice president of Macronex, 919-481-4390, or Anthony J. Russo, Ph.D. of Noonan/Russo Communications, 212-979-9180, for Macronex/ CO: Macronex, Inc. ST: North Carolina IN: MTC SU: PER


TS-SH -- NY010 -- 0816 10/16/92 09:33 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 16, 1992
Words:369
Previous Article:AMERISCRIBE HOLDS DISCUSSIONS REGARDING POSSIBLE SALE; RESULTS FOR THIRD QUARTER TO BE LOWER THAN ANTICIPATED
Next Article:CASINO AMERICA ANNOUNCES VICKSBURG ACQUISITION
Topics:


Related Articles
MACRONEX ELECTS CEO OF CEPHALON TO BOARD OF DIRECTORS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters